Otsuka Pharmaceutical Factory completes a new factory "MP-VII" for IV solutions, with the world's highest quality and a high production capacity

Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shinichi Ogasawara) has completed a new factory "MP-VII" on the site of Matsushige Factory (Matsushige-cho, Itano, Tokushima, Japan) which will manufacture IV solutions, or ethical drugs. The completion ceremony was held on November 12, 2020.

We have put our technical expertise of a leading company in IV solutions into MP-VII as a new factory on the Matsushige Factory site to create a new manufacturing line by introducing new container and new manufacturing technology. After an approximately 2-year construction period since its inception in February 2018, we have started manufacturing dual-chamber infusion bags since July of this year. It has a high-quality and high-production capacity in compliance with the global standards PIC/S^*1 GMP,^*2 and we expect it to serve as one of our main factories in the future.

Our main products, IV solutions, are used in various clinical departments as fundamental and important life-sustaining drugs, and we are required to provide safe and high-quality products with a stable supply. In order to provide stable products that contribute to the health and nutrition management of people, we will continue to promote the development of new products, the improvement of products, and the enhancement of production facilities, with the aim of becoming the best partner for patients and healthcare professionals in the field of clinical nutrition.

Based on the corporate philosophy of "Otsuka-people creating new products for better health worldwide," the Otsuka Group is dedicated to contributing to the health of people around the world.

※１　PIC/S (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme): An unofficial cooperative framework between inspection authorities intended to internationally develop, implement, and secure the harmonized pharmaceutical field's GMP standards and quality assurance systems for inspection authorities. The Scheme was formed in 1970, and as of March 2020, it has 55 member authorities, including Japan's entry in 2014.

※２　GMP (Good Manufacturing Practice): The standards for manufacturing and quality control of medicinal products.